275 related articles for article (PubMed ID: 21514795)
1. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
[TBL] [Abstract][Full Text] [Related]
2. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
Moody JA; Gerding DN; Peterson LR
Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
[TBL] [Abstract][Full Text] [Related]
5. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
6. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa.
Ozbek B; Otuk G
Chemotherapy; 2009; 55(6):446-50. PubMed ID: 19996590
[TBL] [Abstract][Full Text] [Related]
7. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
Drago L; De Vecchi E; Nicola L; Colombo A; Guerra A; Gismondo MR
Chemotherapy; 2004 Oct; 50(4):202-10. PubMed ID: 15452399
[TBL] [Abstract][Full Text] [Related]
8. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
Piccoli L; Guerrini M; Felici A; Marchetti F
J Chemother; 2005 Aug; 17(4):355-60. PubMed ID: 16167512
[TBL] [Abstract][Full Text] [Related]
10. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
11. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
12. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
[TBL] [Abstract][Full Text] [Related]
13. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
[TBL] [Abstract][Full Text] [Related]
14. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
15. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
Nazli E; Zer Y; Eksi F
J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
[TBL] [Abstract][Full Text] [Related]
16. Synergistic potential of ceftazidime plus amikacin or levofloxacin against Pseudomonas aeruginosa as determined using a checkerboard and a disk diffusion technique.
Montanari MP; Piccoli L; Mingoia M; Marchetti F; Varaldo PE
Diagn Microbiol Infect Dis; 2005 Oct; 53(2):157-60. PubMed ID: 16168614
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
Yasmin F; Akhtar N; Hameed A
Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
[TBL] [Abstract][Full Text] [Related]
18. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
Lister PD; Wolter DJ; Wickman PA; Reisbig MD
J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
